Making Europe a center for Nanomedicine research, development and translation is the goal of this project. To achieve this goal the proposed project unites partners already representing the largest network of active stakeholders in the Nanomedicine area as of today in Europe, embracing roughly 200 hundred Universities, Research Institutes, Hospitals and Public Health Institutions, Small and Medium-sized Enterprises (SMEs) and Small and Large Industry organizations.
What are the needs and the problems? Excellent academic research groups may need to better understand the market and the medical needs. There are a large number of pharmaceutical and medtech companies that have a comprehensive and direct access to market but these companies struggle to handle radical innovation. At the same time there is a small number of SMEs trying to add new innovation onto the market, but these few companies are too small to exploit the large potential of Nanomedicine. A consolidated pan-European approach to structure this field is therefore highly needed to bring Nanomedicine products more efficiently to patients.
“We are proud that we were able to receive funding for this project from the European Commission” said Dr. Sebastian Lange, the coordinator of this project at VDI/VDE-IT. “Seven renowned Nanomedicine players from six European countries hope to build a pertinent European Nanomedicine community involving all key players. We aim to define the resources, gaps and needs for development and implementation of Nanomedicine research into marketable innovations to be used by doctors for the benefit of patients.”
The NANOMED2020 project is an opportunity for all stakeholders from industry, academia, clinic and public authorities to provide the European Commission with input for a future Nanomedicine topic within Horizon 2020. This will make Nanomedicine an important contributor to the future European healthcare system with a beneficial impact on improved treatment for patients and on social challenges such as ageing population.
The NANOMED2020 Support Action project, funded with a contribution of 500 000€ by the European Commission under the Work Programme FP7-HEALTH-2012 (Area 2012.4.1-5: Preparing the future for health research and innovation) was launched on 1st September 2012 and is planned to have duration of 18 months.
Partners of the NANOMED2020 project:
• ETP Nanomedicine c/o VDI/VDE-IT (Coordinator),
• CLINAM Foundation,
• Instituto de Salud Carlos III,
• Bioanalytik Muenster e.V.,
• Fondazione Don Carlo Gnocchi ONLUS,
For more information about the project consult:
The website www.nanomed2020.eu will be launched soon. Latest news on Nanomedicine research, strategic challenges and innovation concepts will be available there.
Nanomedicine is understood to be the enabling instrument for personalized, targeted and regenerative medicine by delivering the next level of new drugs, treatments and implantable devices to clinicians and patients. Beyond that, Nanomedicine provides important new tools to deal with the grand challenge of an ageing population and is thought to be instrumental for improved and cost effective health-care, one crucial factor for making medicines and treatments available and affordable to all.
ABOUT ETP Nanomedicine c/o VDI/VDE-IT,
VDI/VDE-IT is a leading service provider in the field of innovation and technology for customers in Germany and all over the world. We analyse, support and organise innovation and technology for clients with political, research, industry and finance backgrounds.
Since 2008, VDI/VDE-IT is managing the Office of the European Technology Platform on Nanomedicine, ETPN. This platform was established in 2005 as a joint venture of the European Commission and CEOs of large industrial companies such as Philips, Siemens and UCB, SMEs and academic research institutions to investigate and advance joint activities in the area of nanotechnology in medicine. Since 2005 the ETPN published a number of strategic documents outlining the needs and roadmaps for Nanomedicine research in Europe. The ETPN contributed to set up numerous European funded projects providing a first impression of the conditions for a suitable social and economic environment and the structural requirements for an efficient translation of R&D results into innovative Nanomedicines. The ETPN supports its members in coordinating their joint research efforts and improving communication amongst the members as well as towards the EC and the European Member States.
Dr. Sebastian Lange
+49 30 310078 155